MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

MDT

96.83

-2.02%↓

A

139.62

-3.71%↓

VEEV

222.3

+1.47%↑

HQY

85.02

-2.1%↓

NEOG

9.24

-2.22%↓

Search

Pacific Biosciences of California Inc

Closed

SectorHealthcare

2.21 -4.33

Overview

Share price change

24h

Current

Min

2.21

Max

2.39

Key metrics

By Trading Economics

Income

3.9M

-38M

Sales

-1.3M

38M

Profit margin

-98.853

Employees

575

EBITDA

3.2M

-32M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+12.68% upside

Dividends

By Dow Jones

Next Earnings

12 Feb 2026

Market Stats

By TradingEconomics

Market Cap

-66M

607M

Previous open

6.54

Previous close

2.21

News Sentiment

By Acuity

38%

62%

114 / 361 Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Pacific Biosciences of California Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 Jan 2026, 18:44 UTC

Major Market Movers

Agenus Falls After $141 Million Zydus Deal Closes

15 Jan 2026, 17:51 UTC

Major Market Movers

Galaxy Digital Climbs on Texas Data-Center Expansion Approval, Tokenized CLO Issuance

15 Jan 2026, 17:25 UTC

Major Market Movers

ASML Exceeds $500 Billion in Market Value on TSMC's Blockbuster Spending Plans -- Update

15 Jan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 Jan 2026, 23:48 UTC

Market Talk

Nikkei May Decline as Enthusiasm Over Election Eases -- Market Talk

15 Jan 2026, 23:40 UTC

Market Talk

Gold Edges Lower Amid Abating Geopolitical Risks -- Market Talk

15 Jan 2026, 23:11 UTC

Market Talk

Global Equities Roundup: Market Talk

15 Jan 2026, 23:11 UTC

Market Talk

Ryman Healthcare's Resales Remain Key Concern -- Market Talk

15 Jan 2026, 23:01 UTC

Market Talk

New Zealand's Economy Enters An Upswing -- Market Talk

15 Jan 2026, 22:56 UTC

Market Talk
Earnings

Catalyst Metals Delivers a Beat With Record Gold Output -- Market Talk

15 Jan 2026, 22:51 UTC

Market Talk

James Hardie's Plant Closures Could Boost Profit by 2%-3% -- Market Talk

15 Jan 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Verizon Gets Final California Approval to Secure $9.6 Billion Frontier Deal -- WSJ

15 Jan 2026, 21:50 UTC

Market Talk
Earnings

Financial Services Roundup: Market Talk

15 Jan 2026, 21:50 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Energy & Utilities Roundup: Market Talk

15 Jan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 Jan 2026, 21:27 UTC

Earnings

BlackRock Caps 2025 With Record $14 Trillion in Assets -- 3rd Update

15 Jan 2026, 21:15 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Commodities Roundup: Market Talk

15 Jan 2026, 21:11 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Global Equities Roundup: Market Talk

15 Jan 2026, 21:11 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Canada Antitrust Watchdog Confirms Review of Canadian Energy Deal -- Market Talk

15 Jan 2026, 20:10 UTC

Market Talk

U.S. Natural Gas Futures Settle Mixed -- Market Talk

15 Jan 2026, 20:04 UTC

Earnings

These Stocks Are Today's Movers: TSMC, ASML, Goldman, Morgan Stanley, BlackRock, Coinbase, Sandisk, and More -- Barrons.com

15 Jan 2026, 20:03 UTC

Market Talk

Oil Futures Fall As Iran Risk Premium Fades -- Market Talk

15 Jan 2026, 19:26 UTC

Market Talk

Silver Closes at Fresh High -- Market Talk

15 Jan 2026, 18:29 UTC

Major Market Movers

Agenus Falls After $141M Zydus Deal Closes

15 Jan 2026, 18:20 UTC

Earnings

Wall Street Powers Nation's Biggest Banks to Record Year -- WSJ

15 Jan 2026, 17:56 UTC

Market Talk
Earnings

U.S. Bank Results Look Encouraging for European Peers -- Market Talk

15 Jan 2026, 17:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Auto & Transport Roundup: Market Talk

15 Jan 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

15 Jan 2026, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 Jan 2026, 17:02 UTC

Acquisitions, Mergers, Takeovers

KBC Group Completes Acquisition of 98.45% Stake in 365.bank From J&T Finance Group

Peer Comparison

Price change

Pacific Biosciences of California Inc Forecast

Price Target

By TipRanks

12.68% upside

12 Months Forecast

Average 2.4 USD  12.68%

High 3 USD

Low 2 USD

Based on 5 Wall Street analysts offering 12 month price targets forPacific Biosciences of California Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

3

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

1.13 / N/ASupport & Resistance

Short Term

Bullish Evidence

Intermediate Term

Bearish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

114 / 361 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Pacific Biosciences of California Inc

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
help-icon Live chat